CRL · Charles River Laboratories International Inc.
AI read · Good for CRL
The AI's read
The purchase gives Charles River more work with clinical-stage drug makers. About 75% of its bioanalysis sales come from preclinical programs, compared with 15% from clinical-stage testing. Frontage's operations focus mainly on clinical development, helping balance that mix. The global bioanalysis sector is expected to grow 6% to 8% per year through 2031, and Charles River expects the acquired business to keep pace. The company expects no change to profit per share in 2027, and it plans to use cash and borrowing. Those costs and the delayed payoff temper the benefit, but the added clinical work and growth opportunity make the deal favorable.